share_log

Retail Investors Invested in SMO ClinPlus CO.,LTD. (SZSE:301257) Copped the Brunt of Last Week's CN¥379m Market Cap Decline

Retail Investors Invested in SMO ClinPlus CO.,LTD. (SZSE:301257) Copped the Brunt of Last Week's CN¥379m Market Cap Decline

散戶投資者投資了 SMO ClinPlus CO.,有限公司(SZSE: 301257) 首當其衝地應對了上週3.79億人民幣市值下跌的衝擊
Simply Wall St ·  03/27 18:10

Key Insights

關鍵見解

  • The considerable ownership by retail investors in SMO ClinPlusLTD indicates that they collectively have a greater say in management and business strategy
  • A total of 6 investors have a majority stake in the company with 51% ownership
  • Insiders own 13% of SMO ClinPlusLTD
  • 散戶投資者對SMO ClinplusLtd的大量所有權表明,他們在管理和業務戰略中共同擁有更大的發言權。
  • 共有6位投資者持有該公司的多數股權,所有權爲51%
  • 內部人士擁有SMO ClinplusLtd13%的股份

To get a sense of who is truly in control of SMO ClinPlus CO.,LTD. (SZSE:301257), it is important to understand the ownership structure of the business. With 28% stake, retail investors possess the maximum shares in the company. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

了解誰真正控制了 SMO ClinPlus CO., LTD.(深圳證券交易所代碼:301257),了解企業的所有權結構很重要。散戶投資者擁有公司的最大股份,持有28%的股份。換句話說,該集團將從對公司的投資中獲得最多(或損失最大)。

As market cap fell to CN¥2.9b last week, retail investors would have faced the highest losses than any other shareholder groups of the company.

隨着上週市值跌至29億元人民幣,散戶投資者面臨的損失將超過該公司任何其他股東群體。

Let's take a closer look to see what the different types of shareholders can tell us about SMO ClinPlusLTD.

讓我們仔細看看不同類型的股東能告訴我們關於SMO ClinplusLtd的信息。

ownership-breakdown
SZSE:301257 Ownership Breakdown March 27th 2024
SZSE: 301257 所有權明細 2024 年 3 月 27 日

What Does The Institutional Ownership Tell Us About SMO ClinPlusLTD?

關於SMO ClinplusLtd,機構所有權告訴我們什麼?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

機構投資者通常將自己的回報與常見指數的回報進行比較。因此,他們通常會考慮收購相關基準指數中包含的大型公司。

We can see that SMO ClinPlusLTD does have institutional investors; and they hold a good portion of the company's stock. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of SMO ClinPlusLTD, (below). Of course, keep in mind that there are other factors to consider, too.

我們可以看到,SMO ClinplusLtd確實有機構投資者;他們持有該公司很大一部分股票。這意味着在這些機構工作的分析師已經看過這隻股票,他們很喜歡。但是就像其他人一樣,他們可能錯了。如果兩個大型機構投資者試圖同時拋售股票,股價大幅下跌的情況並不少見。因此,值得查看一下SMO ClinplusLtd過去的收益軌跡(見下文)。當然,請記住,還有其他因素需要考慮。

earnings-and-revenue-growth
SZSE:301257 Earnings and Revenue Growth March 27th 2024
SZSE: 301257 2024年3月27日收益和收入增長

We note that hedge funds don't have a meaningful investment in SMO ClinPlusLTD. Shanghai Xibao Investment Management Co., Ltd. is currently the company's largest shareholder with 19% of shares outstanding. With 8.0% and 7.9% of the shares outstanding respectively, Shihezi Ruixin Equity Investment Partnership Enterprise (Limited Partnership) and Shanghai Guanyou Investment and Development Co., Ltd. are the second and third largest shareholders.

我們注意到,對沖基金沒有對SMO ClinplusLtd進行有意義的投資。上海西寶投資管理有限公司目前是該公司的最大股東,已發行股份的19%。石河子瑞信股權投資合夥企業(有限合夥)和上海冠友投資發展有限公司分別佔已發行股份的8.0%和7.9%,是第二和第三大股東。

We did some more digging and found that 6 of the top shareholders account for roughly 51% of the register, implying that along with larger shareholders, there are a few smaller shareholders, thereby balancing out each others interests somewhat.

我們做了進一步的挖掘,發現大股東中有6人約佔登記冊的51%,這意味着除了較大的股東外,還有一些較小的股東,從而在一定程度上平衡了彼此的利益。

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. As far as we can tell there isn't analyst coverage of the company, so it is probably flying under the radar.

雖然研究公司的機構所有權可以爲您的研究增加價值,但研究分析師的建議以更深入地了解股票的預期表現也是一種好做法。據我們所知,沒有分析師對該公司進行報道,因此它可能處於雷達之下。

Insider Ownership Of SMO ClinPlusLTD

SMO ClinplusLtd 的內部所有權

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

公司內部人員的定義可能是主觀的,並且在不同的司法管轄區之間確實有所不同。我們的數據反映了個人內部人士,至少涵蓋了董事會成員。管理層最終對董事會負責。但是,經理成爲執行委員會成員的情況並不少見,尤其是當他們是創始人或首席執行官時。

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

當內部所有權表明領導層像公司的真正所有者一樣思考時,內部所有權是積極的。但是,高度的內部所有權也可以賦予公司內部的一小部分人巨大的權力。在某些情況下,這可能是負面的。

Our information suggests that insiders maintain a significant holding in SMO ClinPlus CO.,LTD.. Insiders own CN¥392m worth of shares in the CN¥2.9b company. We would say this shows alignment with shareholders, but it is worth noting that the company is still quite small; some insiders may have founded the business. You can click here to see if those insiders have been buying or selling.

我們的信息表明,內部人士持有SMO ClinPlus CO的大量股份。, LTD.。內部人士擁有這家29億元人民幣公司價值3.92億元人民幣的股份。我們可以說這表明了與股東的一致性,但值得注意的是,該公司仍然很小;一些內部人士可能已經創立了該公司。你可以點擊這裏查看這些內部人士是否在買入或賣出。

General Public Ownership

一般公有制

With a 28% ownership, the general public, mostly comprising of individual investors, have some degree of sway over SMO ClinPlusLTD. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.

SMO ClinplusLtd擁有28%的所有權,主要由個人投資者組成的公衆對SMO ClinplusLtd有一定程度的影響力。儘管這個群體不一定能做主,但它肯定會對公司的運作方式產生真正的影響。

Private Equity Ownership

私募股權所有權

With an ownership of 26%, private equity firms are in a position to play a role in shaping corporate strategy with a focus on value creation. Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. Alternatively, those holders might be exiting the investment after taking it public.

私募股權公司擁有26%的所有權,可以在制定以價值創造爲重點的公司戰略方面發揮作用。一些投資者可能會爲此感到鼓舞,因爲私募股權有時能夠鼓勵制定有助於市場看到公司價值的策略。或者,這些持有人可能會在投資上市後退出投資。

Private Company Ownership

私人公司所有權

Our data indicates that Private Companies hold 8.0%, of the company's shares. It might be worth looking deeper into this. If related parties, such as insiders, have an interest in one of these private companies, that should be disclosed in the annual report. Private companies may also have a strategic interest in the company.

我們的數據顯示,私人公司持有公司8.0%的股份。可能值得對此進行更深入的研究。如果關聯方,例如內部人士,對其中一傢俬營公司有興趣,則應在年度報告中予以披露。私營公司也可能在公司中擁有戰略利益。

Next Steps:

後續步驟:

While it is well worth considering the different groups that own a company, there are other factors that are even more important.

雖然值得考慮擁有公司的不同群體,但還有其他更爲重要的因素。

Many find it useful to take an in depth look at how a company has performed in the past. You can access this detailed graph of past earnings, revenue and cash flow.

許多人發現,深入了解一家公司過去的表現很有用。您可以訪問這張過去的收益、收入和現金流的詳細圖表。

If you would prefer check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, backed by strong financial data.

如果你更願意去另一家公司看看,一家財務狀況可能更好,那麼千萬不要錯過這份由強勁財務數據支持的有趣公司的免費名單。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注意:本文中的數字是使用過去十二個月的數據計算得出的,這些數據是指截至財務報表日期當月最後一天的12個月期間。這可能與全年年度報告數據不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論